Navigation Links
Bacterin International Holdings Secures $5,000,000 Credit Facility with Bridge Bank
Date:1/20/2011

BELGRADE, Mont., Jan. 20, 2011 /PRNewswire/ -- Bacterin International Holdings, Inc. ("Bacterin") (OTC Bulletin Board: BIHI), today announced that it has closed on the Bridge Bank, N.A. revolving accounts receivable line of credit facility for up to $5 million that was announced on November 22, 2010.  The financing, which is secured by the Company's accounts receivable and other assets, has a 2 year term and carries an interest rate of the Bridge Bank prime rate plus 2.25%.  The draw-down of funds is based upon borrowing up to 80 percent of eligible accounts receivable subject to typical borrowing base and asset coverage restrictions and other performance milestones.

Founded in 2001, Bridge Bank (Nasdaq: BBNK) is a full service professional business bank dedicated to meeting the financial needs of small, middle-market, and emerging technology businesses in Silicon Valley, California, and the nation.  

The credit facility with Bridge Bank follows the announcement of an asset backed lending facility of up to $8 million with Western Technology Investment ("WTI") that was completed on November 22, 2010.  WTI provided Bacterin an immediate draw-down of $2.5 million in November, 2010.  The WTI facility offers an additional $2.5 million through April 30, 2011, upon the achievement of certain performance based milestones through March 31, 2011. The agreement also contains provisions for the potential draw-down of up to $3 million based upon Bacterin raising additional levels of equity capital.

John Gandolfo, CFO of Bacterin commented, "The completion of this credit facility with Bridge Bank provides Bacterin with the additional capital to execute on our current growth plans.  We expect to utilize the proceeds of the facility for general working capital purposes and to cover the cost of expected increases in inventory purchases as our revenues and hospital account base continue to grow.  Our product penetration into hospitals is indeed gaining momentum.  During the fourth quarter of 2010, we secured an additional 177 hospitals that now stock Bacterin biologic product on their shelves, versus 96 new hospital accounts in the prior third quarter period."  

About Bacterin International Holdings, Inc.

Bacterin International Holdings, Inc. ("Bacterin") develops, manufactures and markets biologics products to domestic and international markets.  Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold and promote bone and other tissue growth.  These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain by facet joint stabilization, promotion of bone fusion in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral bone defect repair in articulating joint surgeries.

Bacterin's Medical Device division develops anti-microbial coatings based upon proprietary coating technologies. Bacterin develops, employs, and licenses bioactive coatings for various medical device applications.  Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination.

Headquartered in Belgrade, Montana, Bacterin operates a 32,000 square foot, state-of-the-art, fully compliant and FDA registered facility, equipped with four "Class 100" clean rooms.  For further information please visit www.bacterin.com.

Certain statements in this news release may constitute "forward-looking" statements within the meaning of section 21E of the Securities and Exchange Act of 1934.  Our forward-looking statements include earnings guidance and other statements regarding our expectations and beliefs.  The Company believes that its expectations, as expressed in these statements are based on reasonable assumptions regarding the risks and uncertainties inherent in achieving those expectations.  These statements are not, however, guarantees of future performance and actual results may differ materially. Risks and uncertainties which may cause actual results to be different than expressed or implied in our forward-looking statements include, but are not limited to, the risk factors described under the heading "Risk Factors" in Amendment No. 2 to our Form S-1 filed January 7, 2011.  The Company expressly disclaims any current intention to update any forward-looking statements as a result of new information or future events or developments.


'/>"/>
SOURCE Bacterin International Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Bacterin International Reconstitutes Its Board of Directors and Appoints Experienced Legal and Financial Professionals
2. Bacterin International Appoints Three New Members to Its Board of Directors
3. 4th International Conference on Electrophoretic Deposition
4. Verenium Announces Favorable Outcome of Capital Ventures International Lawsuit
5. Cellular Dynamics International to Present at 29th Annual JPMorgan Healthcare Conference
6. Halt Medical Presents Strong Results of International Fibroid Studies at National Institutes of Health Global Congress
7. Web of international collaboration boosts worldwide nanotechnology research
8. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
9. Egon Zehnder International Names Todd Hutchings to Lead Life Sciences Practice Group
10. Nu Skin Scientists Present ageLOC Research at International Conference on Mitochondria
11. Medizone International Secures $10,000,000 Funding Commitment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Dr. Robert G. Schwartz, the ... announced today that acclaimed physiatrist Matthew Terzella, MD, has joined the practice as ... Dr. Terzella completed his residency in Physical Medicine and Rehabilitation at UMDNJ-Robert Wood ...
(Date:4/24/2017)... -- Dante Labs announced today the offer of whole genome sequencing ... American individuals have been able to access WGS at $1,000, ... below EUR 1,000. The sequencing includes bioinformatics analysis ... make informed decisions about disease monitoring, prevention, nutrition, exercise, health ... ...
(Date:4/21/2017)... ANAHEIM, California, and BELLINGHAM, Washington, USA (PRWEB) , ... ... ... of photonics technologies for sensing, imaging, and related applications were the focus of ... Defense and Commercial Sensing 2017 in Anaheim. , Sponsored by SPIE, ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... this new webinar will explore challenging patient cases when screening for direct oral ... there may be a need for bridging parental anticoagulation especially for those at ...
Breaking Biology Technology:
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
Breaking Biology News(10 mins):